To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

MicroRNA-155 is upregulat… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

MicroRNA-155 is upregulated in MLL-rearranged AML but its absence does not affect leukemia development.

Journal article
Authors Edith Schneider
Anna Staffas
Linda Röhner
Kathrin Krowiorz
Michael Heuser
Konstanze Döhner
Lars Bullinger
Hartmut Döhner
Linda Fogelstrand
Arefeh Rouhi
Florian Kuchenbauer
Lars Palmqvist
Published in Experimental hematology
Volume 44
Issue 12
Pages 1166-71
ISSN 1873-2399
Publication year 2016
Published at Institute of Biomedicine, Department of Clinical Chemistry and Transfusion Medicine
Pages 1166-71
Language en
Keywords AML, MLL, miRNA
Subject categories Molecular medicine (genetics and pathology), Molecular biology, Hematology


MicroRNA-155 (miR-155) is an oncogenic miRNA upregulated in various tumor types and leukemias and has been suggested as a potential drug target. Based on our previous work detecting high miR-155 levels in response to Meis1 overexpression in a murine Hox leukemia model, we show here the relationship among HOXA9, MEIS1, and miR-155 levels in MLL-translocated acute myeloid leukemia (AML) patients. Using mouse bone marrow cells transformed by MLL-fusion genes expressing graduated levels of Meis1, we show a positive correlation between miR-155 and Meis1. However, using a miR-155-knockout mouse model, we show that the absence and the depletion of miR-155 have no effect on leukemia formation or progression. We also show for the first time that miR-155 levels are correlated with MLL translocations, but that miR-155 expression is dispensable for the formation of AML and has no effect on leukemia progression.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?